EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
And The Ride Hasn't Got Any Smoother In Recent Times Over The Last Year, With The Price 25% Lower In That Time . Furthermore, It's Down 11% in About a Quarter. That's Not Much Fun For Holders . ...